AACR 2023 highlights: why targeting KRAS is essential

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, provides his highlights at the American Association for Cancer Research (AACR) Annual Meeting 2023, including a plenary session on targeting KRAS mutations. KRAS is highly important in signalling pathways, and multiple trials are underway assessing KRAS inhibitors. This interview took place at AACR 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.